This study is for people with relapsing-remitting multiple sclerosis (RRMS). RRMS is a type of multiple sclerosis where people have periods of new or worsening symptoms, called relapses, followed by times of recovery. The study will test a new drug called PIPE-307 against a placebo, which is a harmless pill with no medicine. It will last about 30 weeks, including a 28-day screening period and 26 weeks of treatment.

Participants will be divided into three groups: two groups will receive different doses of PIPE-307, and one group will receive a placebo. Doctors will check participants' health using tests like checking heartbeat, taking blood samples, and doing physical and brain exams. These tests help ensure the drug is safe.

• Study lasts around 30 weeks, including screening and treatment.
• Participants will receive either PIPE-307 or a placebo.
• Health checks include blood tests and exams for safety.

To join, you must speak English, be aged 18-50, and have RRMS. You cannot join if you've had optic neuritis recently, have certain eye conditions, or have used specific medications or treatments.